Back to News
Market Impact: 0.25
J&J's RYBREVANT FASPRO Combo Delivers 77% Response Rate In Head And Neck Cancer
Source: Nasdaq
Healthcare & Biotech
Johnson & Johnson reported that Phase 1b/2 results showed substantial anti-tumor activity for RYBREVANT FASPRO combined with pembrolizumab and carboplatin in first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. The provided article text contains no efficacy figures or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
JNJ0.50
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers